Kidney and liver contributions to salicylate metabolism in rats

  • M. Lázníček
  • A. Lázníčková


The pharmacokinetics and metabolism of radiolabelled salicylate were studied in rats and compared with that of the isolated perfused rat liver and the perfused rat kidney. Both parent compound and salicylate metabolites (mainly conjugates with glycine and glucuronic acid) were eliminated mostly into urine. The comparison of a relative proportion of metabolites eliminated in whole rats with that of the isolated perfused rat liver and the perfused rat kidney showed that both kidney and liver contributed to the salicylate metabolism. The glycine conjugate of salicylate was formed predominantly in the kidney whereas both kidney and liver participated in the formation of glucuronic acid derivatives.


Salicylate pharmacokinetics metabolism perfused rat liver perfused rat kidney 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Needs C.J., Brooks P.M. (1985): Clinical pharmacokinetics of salicylates. Clin. Pharmacokinet., 10, 164–177.CrossRefPubMedGoogle Scholar
  2. 2.
    Levy G. (1979): Pharmacokinetics of salicylate in man. Drug Metab. Rev., 9, 3–19.CrossRefPubMedGoogle Scholar
  3. 3.
    Wan S.H., Riegelman S. (1972): Renal contribution to overall metabolism of drugs. II. Biotransformation of salicylic acid to salicyluric acid. J. Pharm. Sci., 61, 1284–1287.CrossRefPubMedGoogle Scholar
  4. 4.
    Bekersky I., Colburn W.A., Fishman L., Kaplan S.A. (1980): Metabolism of salicylic acid in the isolated perfused rat kidney. Drug Metab. Dispos., 8, 319–324.PubMedGoogle Scholar
  5. 5.
    Lázníčková A., Karlíček R., Květina J., Kronrád L., Kusák V. (1984):99mTc complexes of ethylenediaminetetra-acetic and ethylenediaminetetra-acetohydroxamic acids; labelling and biodistribution. Int. J. Nucl. Med. Biol., 11, 170–174.CrossRefPubMedGoogle Scholar
  6. 6.
    Lázníček M., Květina J. (1988): The effect of molecular structure on the distribution and elimination of some organic acids in rats. Quant. Struct. Act. Relat., 7, 234–239.CrossRefGoogle Scholar
  7. 7.
    Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. (1981): A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharm. Dyn., 4, 879–885.Google Scholar
  8. 8.
    Lázníček M., Lázníčková A., Květina J. (1990): The contribution of the kidney and liver to the total metabolism of (125I)ortho-iodobenzoate in rats. (in Czech). Českoslov. Farm., 39, 353–356.Google Scholar
  9. 9.
    Lázníček M., Senius K.E.O. (1986): Protein binding of tolfenamic acid in the plasma from patients with renal and hepatic disease. Eur. J. Clin. Pharmacol., 30, 591–596.CrossRefPubMedGoogle Scholar
  10. 10.
    Levy G. (1965): Pharmacokinetics of salicylate elimination in man. J. Pharm. Sci., 54, 959–967.CrossRefPubMedGoogle Scholar
  11. 11.
    Pacifici G.M., Franchi M., Bencini C., Repetti F., Di Lascio N., Muraro G.B. (1988): Tissue distribution of drug-metabolizing enzymes in humans. Xenobiotica, 18, 849–856.CrossRefPubMedGoogle Scholar
  12. 12.
    Tsuchiya T., Levy G. (1972): Relationship between dose and plateau levels of drugs eliminated by parallel first order and capacity limited kinetics. J. Pharm. Sci., 61, 541–544.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • M. Lázníček
    • 1
  • A. Lázníčková
    • 1
  1. 1.Faculty of PharmacyCharles UniversityHradec KrálovéCzechoslovakia

Personalised recommendations